Shanghai RAAS Blood Products Co., Ltd. manufactures and distributes blood products in China and internationally. More Details
Flawless balance sheet with proven track record.
Share Price & News
How has Shanghai RAAS Blood Products's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 002252 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 002252's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 002252 underperformed the CN Biotechs industry which returned 35.6% over the past year.
Return vs Market: 002252 underperformed the CN Market which returned 27.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Shanghai RAAS Blood Products's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Shanghai RAAS Blood Products undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 002252 (CN¥7.32) is trading above our estimate of fair value (CN¥3.62)
Significantly Below Fair Value: 002252 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 002252 is good value based on its PE Ratio (40.6x) compared to the CN Biotechs industry average (56x).
PE vs Market: 002252 is poor value based on its PE Ratio (40.6x) compared to the CN market (34.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 002252's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 002252 is good value based on its PB Ratio (1.9x) compared to the CN Biotechs industry average (6.1x).
How is Shanghai RAAS Blood Products forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shanghai RAAS Blood Products has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Shanghai RAAS Blood Products performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 002252 has high quality earnings.
Growing Profit Margin: 002252's current net profit margins (40.5%) are higher than last year (16.5%).
Past Earnings Growth Analysis
Earnings Trend: 002252's earnings have declined by 28.9% per year over the past 5 years.
Accelerating Growth: 002252's earnings growth over the past year (186.7%) exceeds its 5-year average (-28.9% per year).
Earnings vs Industry: 002252 earnings growth over the past year (186.7%) exceeded the Biotechs industry 16.3%.
Return on Equity
High ROE: 002252's Return on Equity (4.2%) is considered low.
How is Shanghai RAAS Blood Products's financial position?
Financial Position Analysis
Short Term Liabilities: 002252's short term assets (CN¥5.2B) exceed its short term liabilities (CN¥240.0M).
Long Term Liabilities: 002252's short term assets (CN¥5.2B) exceed its long term liabilities (CN¥40.5M).
Debt to Equity History and Analysis
Debt Level: 002252's debt to equity ratio (0.03%) is considered satisfactory.
Reducing Debt: 002252's debt to equity ratio has reduced from 3.5% to 0.03% over the past 5 years.
Debt Coverage: 002252's debt is well covered by operating cash flow (12370.2%).
Interest Coverage: 002252 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Shanghai RAAS Blood Products's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 002252's dividend (0.14%) isn’t notable compared to the bottom 25% of dividend payers in the CN market (0.42%).
High Dividend: 002252's dividend (0.14%) is low compared to the top 25% of dividend payers in the CN market (1.79%).
Stability and Growth of Payments
Stable Dividend: 002252 is not paying a notable dividend for the CN market, therefore no need to check if payments are stable.
Growing Dividend: 002252 is not paying a notable dividend for the CN market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 002252 is not paying a notable dividend for the CN market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 002252's dividend in 3 years as they are not forecast to pay a notable one for the CN market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Jun Xu serves as General Manager and Director of Shanghai RAAS Blood Products Co., Ltd Mr. Jun Xu served as Deputy General Manager of Shanghai RAAS Blood Products Co., Ltd. since April 19, 2013.
Experienced Management: 002252's management team is seasoned and experienced (8 years average tenure).
Experienced Board: 002252's board of directors are considered experienced (8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Shanghai RAAS Blood Products Co., Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Shanghai RAAS Blood Products Co., Ltd.
- Ticker: 2252
- Exchange: SZSE
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥49.343b
- Shares outstanding: 6.74b
- Website: https://www.raas-corp.com
Number of Employees
- Shanghai RAAS Blood Products Co., Ltd.
- No. 2009, Wangyuan Road
- Fengxian District
Shanghai RAAS Blood Products Co., Ltd. manufactures and distributes blood products in China and internationally. It offers human albumin, human immunoglobulin, coagulation factor, and other products. The c...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/11 09:04|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.